111 related articles for article (PubMed ID: 17888616)
1. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
Payer J; Killinger Z; Sulková I; Celec P
Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic adherence to bisphosphonates.
Payer J; Killinger Z; Ivana Sulková ; Celec P
Biomed Pharmacother; 2007 May; 61(4):191-3. PubMed ID: 17412550
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
4. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
[TBL] [Abstract][Full Text] [Related]
5. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
6. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults.
Richards JB; Cherkas LF; Spector TD
Curr Med Res Opin; 2007 Feb; 23(2):293-9. PubMed ID: 17288683
[TBL] [Abstract][Full Text] [Related]
7. Compliance with treatment in osteoporosis patients--an ongoing problem.
Sambrook P
Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
[TBL] [Abstract][Full Text] [Related]
8. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
9. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
10. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
11. Survey of bisphosphonate regimen preferences in an urban community health center.
Ryzner KL; Burkiewicz JS; Griffin BL; Komperda KE
Consult Pharm; 2010 Oct; 25(10):671-5. PubMed ID: 21030357
[TBL] [Abstract][Full Text] [Related]
12. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
13. [Further characterization between oral bisphosphonate dosing interval and patient preference--patient preference for daily, weekly and monthly bisphosphonate, based on results of 3,052 outpatients questionnaires].
Ijiri S
Nihon Rinsho; 2013 Dec; 71(12):2223-31. PubMed ID: 24437282
[TBL] [Abstract][Full Text] [Related]
14. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
15. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
16. Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates--the VIVA II study.
Payer J; Cierny D; Killinger Z; Sulková I; Behuliak M; Celec P
J Int Med Res; 2009; 37(4):1225-9. PubMed ID: 19761708
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
18. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
[TBL] [Abstract][Full Text] [Related]
19. Is there an advantage to an injected bisphosphonate versus a daily or monthly oral regimen?
Mayo Clin Womens Healthsource; 2008 Sep; 12(9):8. PubMed ID: 18667976
[No Abstract] [Full Text] [Related]
20. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
